Büsche G - Search Results

1

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.

Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B. Göhring G, et al. Among authors: busche g. Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24. Ann Hematol. 2010. PMID: 19855965

2

Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan.

Kreft A, Nolde C, Büsche G, Buhr T, Kreipe H, Georgii A. Kreft A, et al. Among authors: busche g. Eur J Haematol. 2000 Jan;64(1):32-41. doi: 10.1034/j.1600-0609.2000.90031.x. Eur J Haematol. 2000. PMID: 10680703

3

Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration.

Schöffski P, Ganser A, Pascheberg U, Büsche G, Gaede B, Hertenstein B. Schöffski P, et al. Among authors: busche g. Ann Hematol. 2000 Feb;79(2):95-8. doi: 10.1007/s002770050018. Ann Hematol. 2000. PMID: 10741923

4

[Incidence and differential diagnosis of chronic eosinophilic leukemia].

Büsche G, Nolte M, Schlue J, Kreft A, Kreipe HH. Büsche G, et al. Pathologe. 2002 Nov;23(6):419-25. doi: 10.1007/s00292-002-0583-8. Epub 2002 Oct 18. Pathologe. 2002. PMID: 12436294 German.

5

[The development of myelofibrosis in prefibrotic cIMF. An investigation of the progression by sequential bone marrow biopsies in 38 patients].

Buhr T, Länger F, Kreft A, Büsche G, Choritz H, Kreipe H. Buhr T, et al. Among authors: busche g. Pathologe. 2002 Nov;23(6):433-7. doi: 10.1007/s00292-002-0582-9. Epub 2002 Oct 19. Pathologe. 2002. PMID: 12436296 German.

6

Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.

Buhr T, Büsche G, Choritz H, Länger F, Kreipe H. Buhr T, et al. Among authors: busche g. Am J Clin Pathol. 2003 Jan;119(1):152-8. doi: 10.1309/PTVG-B3DX-B8A8-M7KD. Am J Clin Pathol. 2003. PMID: 12520711

7

Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis.

Bock O, Neusch M, Büsche G, Mengel M, Kreipe H. Bock O, et al. Among authors: busche g. Eur J Haematol. 2004 Apr;72(4):239-44. doi: 10.1046/j.0902-4441.2003.00204.x. Eur J Haematol. 2004. PMID: 15089760

8

Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.

Bock O, Schlué J, Mengel M, Büsche G, Serinsöz E, Kreipe H. Bock O, et al. Among authors: busche g. J Pathol. 2004 May;203(1):609-15. doi: 10.1002/path.1558. J Pathol. 2004. PMID: 15095485

9

Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia.

Serinsöz E, Neusch M, Büsche G, Wasielewski R, Kreipe H, Bock O. Serinsöz E, et al. Among authors: busche g. Br J Haematol. 2004 Aug;126(3):313-9. doi: 10.1111/j.1365-2141.2004.05049.x. Br J Haematol. 2004. PMID: 15257703 Free article.

10

Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders.

Bock O, Tessema M, Serinsöz E, von Wasielewski R, Büsche G, Kreipe H. Bock O, et al. Among authors: busche g. Leuk Res. 2004 Nov;28(11):1145-51. doi: 10.1016/j.leukres.2004.03.009. Leuk Res. 2004. PMID: 15380337

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters